{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:26Z","timestamp":1791919466963,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/tpj.2015.101","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T11:01:01Z","timestamp":1453806061000},"page":"201-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout"],"prefix":"10.1038","volume":"17","author":[{"given":"R L","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Phipps-Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Topless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T R","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L K","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"BFtpj2015101_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald J, Khanna P, Sangmee B, Singh M, Neogi T et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res 2012; 64: 1431\u20131446.","journal-title":"Arthritis Care Res"},{"key":"BFtpj2015101_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2014.05.007","volume":"44","author":"L Stamp","year":"2014","unstructured":"Stamp L, Merriman T, Barclay M, Singh J, Roberts R, Wright D et al. Inadequate response to allopurinol in the treatment of gout \u2013 defining the population and potential causes. Semin Arthritis Rheum 2014; 44: 170\u2013174.","journal-title":"Semin Arthritis Rheum"},{"key":"BFtpj2015101_CR3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bcp.12126","volume":"76","author":"G Graham","year":"2013","unstructured":"Graham G, Kannangara D, Stocker S, Portek I, Pile K, Indraratna P et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol 2013; 76: 932\u2013938.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj2015101_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2217\/pgs.15.16","volume":"16","author":"R Roberts","year":"2015","unstructured":"Roberts R, Stamp L . Pharmacogenetic considerations in the treatment of gout. Pharmacogenetics 2015; 16: 619\u2013629.","journal-title":"Pharmacogenetics"},{"key":"BFtpj2015101_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.161","volume":"99","author":"Y Saito","year":"2016","unstructured":"Saito Y, Stamp L, Caudle K, Hershfield M, McDonagh M, Callaghan J et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharm Ther 2016; 99: 36\u201337.","journal-title":"Clin Pharm Ther"},{"key":"BFtpj2015101_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cpt.89","volume":"97","author":"C Wen","year":"2015","unstructured":"Wen C, Yee S, Liang X, Hoffmann T, Kvall M, Banda Y et al. Genome-wide association study identifies ABCG2 (BRCP) as an allopurinol transporter and a determinant of drug response. Clin Pharm Ther 2015; 97: 518\u2013525.","journal-title":"Clin Pharm Ther"},{"key":"BFtpj2015101_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"S Wallace","year":"1977","unstructured":"Wallace S, Robinson H, Masi A, Decker J, McCarty D, Yu T . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895\u2013900.","journal-title":"Arthritis Rheum"},{"key":"BFtpj2015101_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"L Stamp","year":"2011","unstructured":"Stamp L, O\u2019Donnell J, Zhang M, James J, Frampton C, Barclay M et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Arthritis Rheum 2011; 63: 412\u2013421.","journal-title":"Arthritis Rheum"},{"key":"BFtpj2015101_CR9","unstructured":"Team RC. A language and environment for statistical computing R Foundation for Statistical Computing2013. Available from http:\/\/www.R-project.org\/."},{"key":"BFtpj2015101_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","volume":"45","author":"M Becker","year":"2015","unstructured":"Becker M, Fitz-Patrick D, Choi H, Dalbeth N, Storgarde C, Cravetsf M et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum 2015; 45: 174\u2013183.","journal-title":"Semin Arthritis Rheum"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj2015101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj2015101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj2015101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:16:55Z","timestamp":1647947815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj2015101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFtpj2015101"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.101","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,26]]},"assertion":[{"value":"12 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dalbeth, Stamp, Merriman and Roberts report grants from the Health Research Council of New Zealand, during the conduct of the study and from Ardea Biosciences for related work that is not part of this manuscript. Dalbeth reports personal fees from Takeda, Teijin, Menarini, Pfizer and Cymabay, grants and personal fees from AstraZeneca, Ardea Biosciences and Fonterra, outside the submitted work. In addition, Dalbeth has a patent Milk Products for Gout pending. Stamp reports consulting fees from Astra Zeneca unrelated to the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}